Want to see RGEN full AI Analyst Report?

Repligen (RGEN) Stock Forecast & Price Target

986 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RGEN Analyst Ratings

Strong Buy

11 Buy

3 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Repligen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RGEN Stock 12 Month Forecast

Average Price Target

$165.36

▲(26.03% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Repligen in the last 3 months. The average price target is $165.36 with a high forecast of $207.00 and a low forecast of $142.00. The average price target represents a 26.03% change from the last price of $131.21.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"116":"$116","139":"$139","162":"$162","185":"$185","208":"$208"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":207,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$207.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":165.36363636363637,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$165.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":142,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$142.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[116,139,162,185,208],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,138.99,144.22153846153847,149.45307692307694,154.6846153846154,159.91615384615386,165.14769230769232,170.3792307692308,175.61076923076922,180.8423076923077,186.07384615384615,191.30538461538464,196.53692307692307,201.76846153846154,{"y":207,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,138.99,141.01874125874127,143.04748251748254,145.0762237762238,147.10496503496503,149.1337062937063,151.16244755244756,153.19118881118882,155.2199300699301,157.24867132867135,159.27741258741258,161.30615384615385,163.3348951048951,{"y":165.36363636363637,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,138.99,139.22153846153847,139.45307692307694,139.6846153846154,139.91615384615386,140.14769230769232,140.3792307692308,140.61076923076922,140.84230769230768,141.07384615384615,141.3053846153846,141.53692307692307,141.76846153846154,{"y":142,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":126.44,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.06,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.86,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.12,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.97,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.32,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.99,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$207.00

Average Price Target$165.36

Lowest Price Target$142.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robert Wasserman

Benchmark Co.

$185

Buy

41.00%

Upside

Upgraded

07/07/26

Repligen upgraded to Buy from Hold at BenchmarkRepligen upgraded to Buy from Hold at Benchmark

Daniel Markowitz CFA

Evercore ISI

$150→$160

Buy

21.94%

Upside

Reiterated

07/06/26

Repligen price target raised to $160 from $150 at Evercore ISIRepligen price target raised to $160 from $150 at Evercore ISI

Luke Sergott

Barclays

$160

Buy

21.94%

Upside

Reiterated

06/24/26

Barclays Sticks to Their Buy Rating for Repligen (RGEN)

Matt Hewitt

Craig-Hallum

―

Buy

―

Reiterated

06/24/26

Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)

Yessica Sanchez Gudino

HSBC

Not Ranked

HSBC

$170→$150

Buy

14.32%

Upside

Reiterated

06/03/26

Repligen price target lowered to $150 from $170 at HSBCRepligen price target lowered to $150 from $170 at HSBC

Michael Polark

Wolfe Research

$145

Buy

10.51%

Upside

Initiated

06/01/26

Repligen assumed with an Outperform at Wolfe ResearchRepligen assumed with an Outperform at Wolfe Research

Dan Leonard

RBC Capital

$160

Buy

21.94%

Upside

Initiated

05/14/26

Repligen resumed with an Outperform at RBC CapitalRepligen resumed with an Outperform at RBC Capital

Matt Larew

William Blair

―

Buy

―

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN), Cardiff Oncology (NASDAQ: CRDF) and Meiragtx Holdings (NASDAQ: MGTX)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

05/07/26

Guggenheim Reaffirms Their Hold Rating on Repligen (RGEN)

Kyle Mikson CFA

Canaccord Genuity

$145

Hold

10.51%

Upside

Reiterated

05/06/26

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Repligen (NASDAQ: RGEN) and Praxis Precision Medicines (NASDAQ: PRAX)

Daniel Arias

Stifel Nicolaus

$207

Buy

57.76%

Upside

Reiterated

05/06/26

Repligen (RGEN) Gets a Buy from Stifel Nicolaus

Casey Woodring

J.P. Morgan

$180→$165

Buy

25.75%

Upside

Reiterated

05/06/26

J.P. Morgan Sticks to Their Buy Rating for Repligen (RGEN)

Brendan Smith

TD Cowen

$200

Buy

52.43%

Upside

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN), Disc Medicine (NASDAQ: IRON) and Cytokinetics (NASDAQ: CYTK)

Matthew Stanton, CFA

Jefferies

$152→$142

Hold

8.22%

Upside

Reiterated

05/05/26

Repligen price target lowered to $142 from $152 at JefferiesRepligen price target lowered to $142 from $152 at Jefferies

Natalya Davies

Rothschild & Co Redburn

$160

Buy

21.94%

Upside

Initiated

04/17/26

Repligen initiated with a Buy at Rothschild & Co RedburnRepligen initiated with a Buy at Rothschild & Co Redburn

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robert Wasserman

Benchmark Co.

$185

Buy

41.00%

Upside

Upgraded

07/07/26

Repligen upgraded to Buy from Hold at BenchmarkRepligen upgraded to Buy from Hold at Benchmark

Daniel Markowitz CFA

Evercore ISI

$150→$160

Buy

21.94%

Upside

Reiterated

07/06/26

Repligen price target raised to $160 from $150 at Evercore ISIRepligen price target raised to $160 from $150 at Evercore ISI

Luke Sergott

Barclays

$160

Buy

21.94%

Upside

Reiterated

06/24/26

Barclays Sticks to Their Buy Rating for Repligen (RGEN)

Matt Hewitt

Craig-Hallum

―

Buy

―

Reiterated

06/24/26

Analysts Conflicted on These Healthcare Names: Repligen (NASDAQ: RGEN), Exelixis (NASDAQ: EXEL) and Ocular Therapeutix (NASDAQ: OCUL)

Yessica Sanchez Gudino

HSBC

Not Ranked

HSBC

$170→$150

Buy

14.32%

Upside

Reiterated

06/03/26

Repligen price target lowered to $150 from $170 at HSBCRepligen price target lowered to $150 from $170 at HSBC

Michael Polark

Wolfe Research

$145

Buy

10.51%

Upside

Initiated

06/01/26

Repligen assumed with an Outperform at Wolfe ResearchRepligen assumed with an Outperform at Wolfe Research

Dan Leonard

RBC Capital

$160

Buy

21.94%

Upside

Initiated

05/14/26

Repligen resumed with an Outperform at RBC CapitalRepligen resumed with an Outperform at RBC Capital

Matt Larew

William Blair

―

Buy

―

Reiterated

05/14/26

Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN), Cardiff Oncology (NASDAQ: CRDF) and Meiragtx Holdings (NASDAQ: MGTX)

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

―

Hold

―

Reiterated

05/07/26

Guggenheim Reaffirms Their Hold Rating on Repligen (RGEN)

Kyle Mikson CFA

Canaccord Genuity

$145

Hold

10.51%

Upside

Reiterated

05/06/26

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Repligen (NASDAQ: RGEN) and Praxis Precision Medicines (NASDAQ: PRAX)

Daniel Arias

Stifel Nicolaus

$207

Buy

57.76%

Upside

Reiterated

05/06/26

Repligen (RGEN) Gets a Buy from Stifel Nicolaus

Casey Woodring

J.P. Morgan

$180→$165

Buy

25.75%

Upside

Reiterated

05/06/26

J.P. Morgan Sticks to Their Buy Rating for Repligen (RGEN)

Brendan Smith

TD Cowen

$200

Buy

52.43%

Upside

Reiterated

05/05/26

Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN), Disc Medicine (NASDAQ: IRON) and Cytokinetics (NASDAQ: CYTK)

Matthew Stanton, CFA

Jefferies

$152→$142

Hold

8.22%

Upside

Reiterated

05/05/26

Repligen price target lowered to $142 from $152 at JefferiesRepligen price target lowered to $142 from $152 at Jefferies

Natalya Davies

Rothschild & Co Redburn

$160

Buy

21.94%

Upside

Initiated

04/17/26

Repligen initiated with a Buy at Rothschild & Co RedburnRepligen initiated with a Buy at Rothschild & Co Redburn

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ENOVEnovis

GKOSGlaukos

IMUXImmunic

AVTXAvalo Therapeutics

TARAProtara Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Repligen

3 Months

Luke SergottBarclays

Success Rate

6/8 ratings generated profit

Average Return

+2.53%

Copying Luke Sergott's trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +2.53% per trade.

1 Year

Luke SergottBarclays

Success Rate

6/8 ratings generated profit

Average Return

+7.51%

Copying Luke Sergott's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +7.51% per trade.

2 Years

Luke SergottBarclays

Success Rate

6/8 ratings generated profit

Average Return

+8.16%

Copying Luke Sergott's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +8.16% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGEN Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RGEN has received 15 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. RGEN average Analyst price target in the past 3 months is 165.36.

Each month's total comprises the sum of three months' worth of ratings.

RGEN Financial Forecast

RGEN Earnings Forecast

Next quarter’s earnings estimate for RGEN is $0.45 with a range of $0.41 to $0.47. The previous quarter’s EPS was $0.48. RGEN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year RGEN has Performed in-line its overall industry.

RGEN Sales Forecast

Next quarter’s sales forecast for RGEN is $201.40M with a range of $199.64M to $203.00M. The previous quarter’s sales results were $194.25M. RGEN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year RGEN has Performed in-line its overall industry.

RGEN Stock Forecast FAQ

What is RGEN’s average 12-month price target, according to analysts?

Based on analyst ratings, Repligen’s 12-month average price target is 165.36.

What is RGEN’s upside potential, based on the analysts’ average price target?

Repligen has 26.03% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RGEN a Buy, Sell or Hold?

Repligen has a consensus rating of Strong Buy which is based on 11 buy ratings, 3 hold ratings and 0 sell ratings.

What is Repligen’s price target?

The average price target for Repligen is 165.36. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $207.00 ,the lowest forecast is $142.00. The average price target represents 26.03% Increase from the current price of $131.21.

What do analysts say about Repligen?

Repligen’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of RGEN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Repligen (RGEN) Stock Forecast & Price Target

RGEN Analyst Ratings

RGEN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Repligen

RGEN Analyst Recommendation Trends

RGEN Financial Forecast

RGEN Earnings Forecast

RGEN Sales Forecast

RGEN Stock Forecast FAQ

Detailed List of Analyst Forecasts